Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Virax Biolabs Group Limited (VRAX)
USD3.45
-0.29 (-7.75%)
GB NASDAQ Healthcare Biotechnology
Address
BioCity Glasgow ML1 5UH
Lanarkshire, SC, GB
Lanarkshire, SC, GB
CEO
James Foster
Website
viraxbiolabs.com
IPO
2022-07-21
CIK 1885827 ISIN KYG9495L1335
Description
Virax Biolabs Group Limited is a biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. The company is developing T cell-based test technologies intended to support an immunology profiling platform, with potential applications in post-acute infection syndromes, including Long COVID, and other chronic conditions linked to immune dysregulation.
News Sentiment (7d)
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD3.45
-0.29 (-7.75%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
1M
Beta
1.33
Float Shares
3.90M
Free Float %
89.9%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -10.63% | -29.60% | +41.22% | -16.95% | -53.03% | -45.32% | -80.70% | -95.17% | -99.90% | -99.90% | -99.90% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (1 ratings, all time)
Buy
Price Targets & DCF
Current price
3.45
Low
1.00
-71.0%
Consensus
1.00
-71.0%
Median
1.00
-71.0%
High
1.00
-71.0%
DCF (Unlevered)
1.26
-63.5%
DCF (Levered)
1.23
-64.3%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | 1 |
1.00
-71.0%
|
| All Time | 1 |
1.00
-71.0%
|
Quality scores
Altman Z-Score
-12.27
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
0 / 10
No MOAT
Composite Rating
B
Overall Score
3 / 5
Medium
DCF Score
5 / 5
High
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
5 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+96.2% ★ Q1'26: -86.5% (vs Q1'24)
-
EPS growth Biotechnology: +29.7%+74.1% ★ Q1'26: +89.6% (vs Q1'24)
-
FCF margin FCF growth · Biotechnology: +16.2%-55,809.3% Q1'26: -18,270.3% (vs Q1'24)
-
EBIT margin Biotechnology: +0.0%-51,515.2% Q1'26: -35,268.2% (vs Q1'24)
-
ROIC Biotechnology: -16.1%-519.8% Q1'26: -1,239.3% (vs Q1'24)
-
Share dilution Biotechnology: -3.4%+220.3% Q1'26: +575.6% (vs Q1'24)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.07× Q1'26: -0.03× (vs Q1'24)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 1 Rev. Ana. 1 EPS Ana. |
Mar 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|
| Revenue |
8.6K
est: 200.0K (-95.7%)
|
156.4K
est: 1.40M (-88.8%)
|
6.3K
est: 25.0K (-74.7%)
|
40.0K
40.0K – 40.0K
+60.0% YoY
|
4.0K
4.0K – 4.0K
-90.0% YoY
|
| EBITDA |
-5.44M
est: -120.0K (-4,435.2%)
|
-6.61M
est: -840.0K (-686.8%)
|
-5.80M
est: -15.0K (-38,582.2%)
|
-24.0K
-24.0K – -24.0K
-60.0% YoY
|
-2.4K
-2.4K – -2.4K
+90.0% YoY
|
| EBIT |
-5.44M
est: -120.0K (-4,435.2%)
|
-6.71M
est: -840.0K (-699.1%)
|
-6.15M
est: -15.0K (-40,871.4%)
|
-24.0K
-24.0K – -24.0K
-60.0% YoY
|
-2.4K
-2.4K – -2.4K
+90.0% YoY
|
| Net Income |
-5.46M
est: -459.3K (-1,088.1%)
|
-6.73M
est: -235.9K (-2,754.8%)
|
-6.06M
est: -4.59M (-32.0%)
|
-1.24M
-1.24M – -1.24M
+73.0% YoY
|
-744.9K
-744.9K – -744.9K
+40.0% YoY
|
| SGA |
5.33M
est: 53.66M (-90.1%)
|
4.59M
est: 375.64M (-98.8%)
|
4.33M
est: 6.71M (-35.4%)
|
10.73M
10.73M – 10.73M
+60.0% YoY
|
1.07M
1.07M – 1.07M
-90.0% YoY
|
| EPS |
-128.25
est: -3.70 (-3,366.2%)
|
-84.00
est: -1.90 (-4,321.1%)
|
-49.00
est: -37.00 (-32.4%)
|
-10.00
-10.00 – -10.00
+73.0% YoY
|
-6.00
-6.00 – -6.00
+40.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-27 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-26 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-22 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-21 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-20 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-19 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-18 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-15 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-14 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-13 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-12 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-11 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-08 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-07 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-06 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-05 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-04 | B | 3/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-01 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-30 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-29 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-28 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-27 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-24 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-23 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-22 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-21 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-20 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-17 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-16 | B- | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-8.75M
OE per share TTM
-2.14
Owner's Yield
-971.21%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
668.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
5
Total invested
12.1K
Insider transactions (90d)
0
Beneficial owners (>5%)
2
Beneficial owners (>5%)
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2025 Q4
Investors holding
5
+1 vs prev Q
New positions
3
Closed positions
2
Increased
4
Reduced
1
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | XTX TOPCO LTD | 21.4K +21.4K (+100.0%) | 7.4K +7.4K (+100.0%) | 0.45% +0.450 pp | 0.00% +0.000 pp | USD0.35 +0.0% | 1 qtrs NEW |
| 2 | UBS GROUP AG | 7.5K +4.1K (+123.0%) | 2.6K +549.0 (+26.9%) | 0.16% +0.049 pp | 0.00% +0.000 pp | USD0.46 -23.9% | 9 qtrs — |
| 3 | NATIONAL BANK OF CANADA /FI/ | 6.0K -4.0K (-40.0%) | 2.1K -3.9K (-65.5%) | 0.13% -0.197 pp | 0.00% +0.000 pp | USD0.70 -50.0% | 3 qtrs — |
| 4 | ADVISOR GROUP HOLDINGS, INC. | 20.00 +20.0 (+100.0%) | 7.00 +7.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD0.30 +16.7% | 1 qtrs NEW |
| 5 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | 10.00 +10.0 (+100.0%) | 3.00 +3.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD0.30 +16.7% | 1 qtrs NEW |
| 6 | VIRTU FINANCIAL LLC | — -21.4K (-100.0%) | — -13.0K (-100.0%) | 0.00% -0.690 pp | 0.00% -0.001 pp | USD— | 2 qtrs SOLD |
| 7 | HRT FINANCIAL LP | — -60.1K (-100.0%) | — -36.0K (-100.0%) | 0.00% -1.940 pp | 0.00% 0.000 pp | USD— | 4 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
0
Sells
0
Shares acquired
—
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+0
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-18 | Norton Evan Michael | Director | — | — | Stock Options (right to buy) | 10,000 | 6.00 | 60.0K | 0 | D | ↗ |
| 2026-03-18 | Miller Iain David | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2026-03-18 | McCracken Nigel William | Director / Officer | — | — | Stock Options (right to buy) | 20,000 | 3.60 | 72.0K | 0 | D | ↗ |
| 2026-03-18 | HAIGHT NELSON M | Director | — | — | Stock Options (right to buy) | 10,000 | 6.00 | 60.0K | 0 | D | ↗ |
| 2026-03-18 | Foster James Alexander Cunliffe | Officer | — | — | Ordinary Shares | 0 | 0.00 | — | 287,987 | D | ↗ |
| 2026-03-18 | Davis Jason | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-3.4K
Shares Outstanding
4.34M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| James Foster | Chairman, Chief Executive Officer & Principal Accounting Officer | 457.4K | male |
| Nigel McCracken | Chief Operating Officer & Director | 448.0K | — |
| Clement Monteil | Head of Scientific Research & Development | — | male |
| Lily Fu | Head of Supply Chain | — | female |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for VRAX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
